April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Mirvetuximab Soravtansine Remains Well Tolerated in Platinum-Resistant Ovarian Cancer
November 15th 2019Kathleen Moore, MD, discusses the findings from the phase III FORWARD-1 trial that investigated mirvetuximab soravtansine in women with folate receptor alpha–positive platinum-resistant ovarian cancer. These findings were presented at the 2019 ESMO Congress.
Watch
DNA-Based NGS Panel Accurately Detects MET Exon 14 Skipping Mutations in NSCLC
November 14th 2019In an interview with Targeted Oncology, Willemina R. Geurts-Giele, PhD, discussed the accuracy of detecting MET exon 14 skipping mutations in patients with NSCLC with DNA-based NGS panels. These findings were presented at The Association for Molecular Pathology Annual Meeting and Expo.
Read More
FDA Grants Orphan Drug Designation to TT-00420 for Treatment of Cholangiocarcinoma
November 8th 2019TT-00420, an investigational spectrum-selective multiple kinase inhibitor received an orphan drug designation from the FDA for the treatment of cholangiocarcinoma, TransThera Biosciences Co. Ltd announced in a press release.
Read More
More Frontline PARP Indications Are Expected in Ovarian Cancer
November 8th 2019PARP inhibitors are increasingly relevant for frontline maintenance indications and potentially in combination with chemotherapy for treatment-naïve ovarian cancer, including for those with <em>BRCA</em>-wildtype disease, Leslie M. Randall, MD, said to the audience at the <em>37th Annual</em> CFS.
Read More
Clinically Important Updates in Cervical Cancer Management
November 7th 2019The American Cancer Society has estimated that in 2019 in the United States, approximately 13,240 new patients will receive a diagnosis of cervical cancer and 4170 individuals will die from the disease. However, because of effective screening programs using cytology and/or high-risk human papillomavirus DNA testing in industrialized nations, incidence and mortality rates have declined.
Read More
Novel Combinations Represent Next Phase for Adult ALL
November 7th 2019A number of promising biologic therapies are beginning to transform the treatment of adult patients with acute lymphoblastic leukemia, with the greatest potential seen with blinatumomab and inotuzumab ozogamicin in combination with chemotherapy, according to a presentation by Hagop M. Kantarjian, MD, at the 37th Annual CFS.<br />
Read More
Despite Only a 50% HPV Vaccination Rate in Adolescents, Cervical Precancer Incidence Rates Drop
November 6th 2019Although a vaccine for the human papillomavirus (HPV) is widely available, an average of 34,800 HPV-associated cancers attributable to the virus, including cervical, vaginal, vulva, penile, anal, and oropharynx were reported in the United States from 2012 through 2016, according to data published in Morbidity and Mortality Weekly Report.
Read More
Determining the Optimal Timing for Immunotherapy in Patients With GEJ Cancers
November 1st 2019Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.
Watch
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
FDA Approves Niraparib for Previously Treated HRD+ Advanced Ovarian Cancer
October 23rd 2019The FDA has approved niraparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with ≥3 prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency positivity.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Treating ALL With Cellular and Targeted Immunotherapies Reduces the Need for Transplant
October 12th 2019The advent of an era of targeted immunotherapy and CAR T-cell therapies for the treatment of adult patients with acute lymphoblastic leukemia may reduce the need for hematopoietic stem cell transplant in certain cases.<br />
Read More
Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer
October 9th 2019The case for the combination of olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, which was covered in 2 separate presentations at the 2019 ESMO Congress.
Read More
Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers
October 8th 2019Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.
Watch
Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7th 2019Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year’s meeting will change the treatment paradigm in a number of patient populations.
Read More
FDA Fast Track Designation Granted to Navicixizumab for Heavily Pretreated Ovarian Cancer
October 7th 2019The FDA has granted a fast track designation to navicixizumab for the treatment of patients with high-grade ovarian, primary peritoneal, or fallopian tube cancer who have received ≥3 prior therapies and/or prior bevacizumab.
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
Trametinib Benefit Promising for Recurrent, Low Grade Ovarian Cancer
October 5th 2019In a randomized trial, treatment with MEK inhibitor trametinib showed significant improvement in progression-free survival and overall survival in patients with recurrent, low-grade serous ovarian cancer.<br />
Read More
ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer
October 4th 2019The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.
Read More
VELIA Trial Shows Benefit for Combination of PARP Plus Chemotherapy in Ovarian Cancer
October 4th 2019Patients with high-grade serous ovarian cancer experienced a 32% reduction in the risk of progression or death with frontline combination veliparib plus carboplatin and paclitaxel followed by veliparib maintenance, according to the data from the phase III VELIA trial presented at the 2019 ESMO Congress, and simultaneously published in the New England Journal of Medicine.
Read More
Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib
October 3rd 2019Using a measure known as the growth modulation index, patients with TRK fusion–positive cancers who were treated with larotrectinib had a clinically meaningful improvement in progression-free survival compared with the time to progression on their prior treatment, an analysis of patients enrolled in 1 of 3 clinical trials has found.
Read More
Blinatumomab Trials Stopped After Benefit is Observed in Pediatric ALL
October 2nd 2019Due to treatment benefit observed in pediatric patients with acute lymphoblastic leukemia, 2 clinical trials investigating blinatumomab (Blincyto) versus chemotherapy were stopped early, according to the drug developer Amgen.
Read More
Nivolumab Plus Ipilimumab Shows Durable Clinical Activity in Cervical Cancer
October 1st 2019In the CheckMate-358 study, the combination of nivolumab and ipilimumab showed durable clinical activity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression.
Read More